CA2001124A1 - Traitement de l'hypertension - Google Patents

Traitement de l'hypertension

Info

Publication number
CA2001124A1
CA2001124A1 CA2001124A CA2001124A CA2001124A1 CA 2001124 A1 CA2001124 A1 CA 2001124A1 CA 2001124 A CA2001124 A CA 2001124A CA 2001124 A CA2001124 A CA 2001124A CA 2001124 A1 CA2001124 A1 CA 2001124A1
Authority
CA
Canada
Prior art keywords
potassium
preferred
hypertension
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2001124A
Other languages
English (en)
Other versions
CA2001124C (fr
Inventor
R. Curtis Morris, Jr.
Anthony Sebastian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2001124A1 publication Critical patent/CA2001124A1/fr
Application granted granted Critical
Publication of CA2001124C publication Critical patent/CA2001124C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002001124A 1988-10-21 1989-10-20 Traitement de l'hypertension Expired - Fee Related CA2001124C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26085688A 1988-10-21 1988-10-21
US260,856 1988-10-21

Publications (2)

Publication Number Publication Date
CA2001124A1 true CA2001124A1 (fr) 1990-04-21
CA2001124C CA2001124C (fr) 2000-01-18

Family

ID=22990921

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002001124A Expired - Fee Related CA2001124C (fr) 1988-10-21 1989-10-20 Traitement de l'hypertension
CA002001123A Expired - Fee Related CA2001123C (fr) 1988-10-21 1989-10-20 Traitement de l'osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002001123A Expired - Fee Related CA2001123C (fr) 1988-10-21 1989-10-20 Traitement de l'osteoporose

Country Status (13)

Country Link
US (1) US5804204A (fr)
EP (3) EP0720855A3 (fr)
JP (2) JP2843146B2 (fr)
KR (2) KR0163583B1 (fr)
AT (1) ATE145825T1 (fr)
AU (2) AU634988B2 (fr)
CA (2) CA2001124C (fr)
DE (2) DE68913311T2 (fr)
DK (2) DK175841B1 (fr)
HU (2) HU208923B (fr)
IL (2) IL92075A (fr)
WO (2) WO1990004403A1 (fr)
ZA (2) ZA898017B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
US20050214387A1 (en) * 2002-04-05 2005-09-29 Naismith Donald J Low-dose potassium supplementation for the prevention and treatment of hypertension
EP1350515A1 (fr) * 2002-04-05 2003-10-08 Btg International Limited Supplément de potassium à faible dose pour la prévention et la thérapie de l'hypertension
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US10251909B2 (en) * 2007-02-09 2019-04-09 Board Of Regents, The University Of Texas System Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
US20090022853A1 (en) * 2007-07-16 2009-01-22 Conopco, Inc., D/B/A Unilever Beverage
RU2010136981A (ru) * 2008-02-06 2012-03-20 Кэмбелл Суп Компани (US) Способы и композиции для снижения содержания натрия в пищевых продуктах
WO2010026136A1 (fr) * 2008-09-05 2010-03-11 Unilever Nv Boissons comprenant du potassium
WO2022073459A1 (fr) * 2020-10-09 2022-04-14 刘志 Formulation pour inhalation et procédé de préparation associé et application correspondante
CN114272263A (zh) * 2022-01-10 2022-04-05 伍永田 一种用于治疗高血压疾病的水配方
CN116819083B (zh) * 2023-06-20 2025-05-27 齐鲁工业大学(山东省科学院) 一种基于重组人肾素分子印迹聚合物的电化学生物传感器、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
GB1195381A (en) * 1967-04-28 1970-06-17 Arthur H Cox & Company Ltd Pharmaceutical Compositions Comprising Potassium and Chlorine
US3639585A (en) * 1968-03-29 1972-02-01 Res Inst Medicine Chem Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method
US3541208A (en) * 1968-09-10 1970-11-17 Arcom Holding Corp Relief of arthritis with a soluble silicate and a soluble polyphosphate
US3921804A (en) * 1974-05-09 1975-11-25 William W Tester Medication dispensing package
SU858830A1 (ru) * 1974-10-23 1981-08-30 Институт медико-биологических проблем Средство дл лечени нарушений ритма сердца
SU946545A1 (ru) * 1978-05-04 1982-07-30 Институт Медико-Биологических Проблем Министерства Здравоохранения Ссср Способ восполнени калиевого дефицита в ткан х
FR2432869A1 (fr) * 1978-08-08 1980-03-07 Armour Montagu Laboratoire Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore
US4405596A (en) * 1978-10-16 1983-09-20 Helbig Joachim W Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
US4704269A (en) * 1985-06-11 1987-11-03 Hudson Pharmaceutical Corporation Effervescent antacid and analgesic compositions
JPH0619063B2 (ja) * 1986-04-09 1994-03-16 日本エステル株式会社 粉体塗料用樹脂組成物

Also Published As

Publication number Publication date
DK72691D0 (da) 1991-04-19
CA2001123A1 (fr) 1990-04-21
DK72791D0 (da) 1991-04-19
KR900701288A (ko) 1990-12-01
ZA898017B (en) 1990-12-28
DE68927519D1 (de) 1997-01-16
DK175840B1 (da) 2005-03-29
JPH04501724A (ja) 1992-03-26
HU896567D0 (en) 1991-07-29
HU896889D0 (en) 1991-07-29
EP0461111B1 (fr) 1994-02-23
CA2001124C (fr) 2000-01-18
HUT57989A (en) 1992-01-28
ZA898018B (en) 1990-12-28
DK72691A (da) 1991-04-22
US5804204A (en) 1998-09-08
DK175841B1 (da) 2005-03-29
IL92076A0 (en) 1990-07-12
DE68913311D1 (de) 1994-03-31
IL92076A (en) 1995-08-31
WO1990004403A1 (fr) 1990-05-03
JP2843146B2 (ja) 1999-01-06
HU208923B (en) 1994-02-28
EP0461111A4 (fr) 1991-07-25
JPH04501419A (ja) 1992-03-12
WO1990004402A1 (fr) 1990-05-03
EP0440738B1 (fr) 1996-12-04
KR0178033B1 (ko) 1999-03-20
AU4622089A (en) 1990-05-14
AU4515489A (en) 1990-05-14
HU212106B (en) 1996-02-28
DE68927519T2 (de) 1997-04-03
CA2001123C (fr) 2000-01-18
EP0720855A3 (fr) 1998-07-08
AU635231B2 (en) 1993-03-18
EP0440738A4 (en) 1991-08-28
IL92075A (en) 1995-07-31
KR900701287A (ko) 1990-12-01
DE68913311T2 (de) 1994-05-26
KR0163583B1 (ko) 1998-12-01
IL92075A0 (en) 1990-07-12
DK72791A (da) 1991-05-14
AU634988B2 (en) 1993-03-11
EP0440738A1 (fr) 1991-08-14
EP0461111A1 (fr) 1991-12-18
ATE145825T1 (de) 1996-12-15
JP2948247B2 (ja) 1999-09-13
EP0720855A2 (fr) 1996-07-10
HUT63058A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
CA2001124A1 (fr) Traitement de l'hypertension
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
PL319370A1 (en) Application of photodynamic therapy for selectively inactivating blood cells and treatment o diseases associated with immunological disturbances
EP0787802A3 (fr)
AU6915396A (en) Multiple sclerosis treatment
JPS57193412A (en) Prevention of prostatic hyperplasia and therapeutical drug
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
IL117882A0 (en) Dermatological preparation and method of treating actinic keratoses
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
CA2154080A1 (fr) Nouveau type d'activite anticoagulante a cofacteur
CA2270558A1 (fr) Traitement de maladies auto-immunes par photochimiotherapie
CA2313618A1 (fr) Formulations transmuqueuses de levosimendane
AU8209987A (en) Hypertension treatment using K+ channel activator and ace inhibitor agents
GR3000751T3 (en) Tpa-containing medical composition and use thereof
IL82317A0 (en) 1,4 dihydropyridine derivatives,processes for their preparation and medicaments containing these compounds
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
RU94020373A (ru) Способ лечения больных ревматоидным артритом
RU94028152A (ru) Способ лечения острого послеабортного эндометрита
MY117556A (en) Methods and formulations for modulating the human sexual response
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
GEP19991514B (en) Method for Treatment with Interferon
IT1255273B (it) 2-azido-carnitina,sua preparazione e suo impiego in terapia umana
ES2148057A1 (es) Nuevo uso del diacepam como potenciador del efecto de los inhibidores pde 3

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed